Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome.
Teoh
S C B
SC
Sharma
S
S
Hogan
A
A
Lee
R
R
Ramanan
A V
AV
Dick
A D
AD
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D000068800:Etanercept; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D007592:Joint Diseases / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013577:Syndrome; D015866:Uveitis, Posterior / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D018124:Receptors, Tumor Necrosis Factor; D011239:Prednisolone; D000068800:Etanercept; D008775:Methylprednisolone; D008727:Methotrexate